PBPK Conference Organizing Committee Members
is a Scientist for Virtual Patients within the Model-Informed Drug Development department at Bayer. He earned his PhD from the University of Münster, Germany, in 2017, and subsequently pursued a postdoctoral fellowship at the University Children’s Hospital in Basel, Switzerland. In 2018, he joined Bayer as a PBPK expert and was elected as a Science Fellow in 2023. Since 2024, he also serves as a full editorial board member of the Journal of Clinical Pharmacology. André has co-authored two book chapters and nearly 60 peer-reviewed articles in collaboration with researchers from academia, industry, and regulatory agencies.
is a Principal PBPK Scientist in the
PBPK Consultancy group at Certara Predictive Technologies. She brings extensive experience across PBPK–PD , DMPK, and clinical pharmacology oversight, supporting drug development and regulatory submissions from early discovery to clinical and post-market stages.
Chara is a strong advocate for integrating PBPK modelling with strategic clinical pharmacology to optimize clinical study design and streamline the drug development process.
is a Senior Principal Scientist in Modeling and Simulation within the Pharmacokinetic Sciences department at Novartis. He is a recognized expert in PBPK, with extensive experience supporting drug development from early clinical phases through registration and life cycle management. Ioannis leads the Pharmacokinetics & Biopharmaceutics Network at Novartis and actively represents the company in cross-industry and academic collaborations, including EFPIA and the IQ Consortium. A key personal achievement includes his pivotal contribution to the successful global regulatory submissions and approvals of asciminib and remibrutinib, where PBPK modeling supported label claims for these first-in-class therapies.
while not a Scientist per se, she has certainly organised (and listened to!) her fair share of events over the years whilst collating a wealth of conference experience along the way! Kelly has worked with Certara Predictive Technologies (CPT) for over 20 years organising conferences, exhibitions, and workshops worldwide. Kelly has been a familiar face at over 100 Certara Predictive Technologies events assisting with logistics, travel and accessing the CPT Simulator.
is a director at Johnson & Johnson, Innovative Medicine specialised in PBPK modelling for 27 years in the Preclinical Sciences and Translational Safety department. She leads a team of modelling scientists providing end-to-end PBPK/PD modelling project support ensuring cross-departmental alignment of model predictions.
serves as the Director, Scientific Product Enablement at Simulations Plus, a global leader in innovative modeling and simulation software for pharmaceutical research and development.
He earned his Pharm.D. from Paris University in 2015 and completed his Ph.D. in 2022. In 2017, Dr. Le Merdy joined the U.S. Food and Drug Administration (FDA) as a postdoctoral fellow in the Division of Quantitative Methods and Modeling within the Office of Generic Drugs. During his time at the FDA, he specialized in PBPK for locally acting drug products, contributing to the advancement of non-oral PBPK methodologies and publishing several papers in this domain.
is a distinguished scientist in translational modelling and simulation which is a part of Pharmaceutical Sciences at Roche Basel. He is with Roche for 27 years where he is a specialist in physiologically based modelling, supporting projects at the preclinical phase leading to first in human dose predictions and then following projects during discovery and development with multiple other PBPK applications.
is an Associate Professor at Department of Anesthesiology, Pharmacology, Intensive Care and Emergencies in the Geneva University Hospital. In 2001, he obtained a PhD in pharmaceutical sciences from the University of Geneva. He joined HUG in 2002 as project manager and head of the clinical pharmacology and toxicology laboratory, where he works on identifying the genetic and environmental sources of variability in drug response. He develops tools for prediction and simulation in special populations using PBPK. In 2014, he also obtained the title of SKPT Clinical Pharmacologist from the Swiss Society of Clinical Pharmacology. He is a member of the Interfaculty Centre for Translational Investigation in Biomarkers (CITB), the Geneva Platelet Group at the Faculty of Medicine and a scientific member of the Cansearch Foundation.
PBPK Conference 2026 